© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Blood Cancer
Positive results for Blincyto, Imbruvica and a bispecific antibody presented at 2022 ASH
December 21, 2022
Results for Amgen’s Blincyto (blinatumomab) suggest it has efficacy as a treatment for Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
CAR-T Therapies Cost Prohibitive for Diffuse Large B-Cell Lymphoma Treatment
December 21, 2022
Researcher modeling the cost effectiveness of chimeric antigen receptor T-cell therapy (CAR-T) therapy and antibody conjugate found that they fell short.
For Multiple Myeloma Patients, Convenience Now an Important Factor in the Treatment Equation
December 20, 2022
The Covid-19 pandemic revealed the advantages of treatment that involved fewer in-person office visits, according to research presented at American Society of Hematology meeting earlier this month. Researchers also saw a notable increase in the use of Darzalex (daratumumab).
Bispecific Antibody Treatments for Multiple Myeloma Are on Their Way
November 15, 2022
Johnson & Johnson’s Tecvayli (teclistamab-cqyv) has been approved by the FDA, and Pfizer’s elranatamab received breakthrough status that should speed its approval. Bispecific antibodies may be a bridge to CAR-T treatments or an alternative to them.
Young Adult Black Patients With Acute Myeloid Leukemia Patients Have Higher Death Rate
November 15, 2022
The younger Black patients with acute myeloid leukemia (AML) had “alarmingly high” early death rates within the first 30 days of study enrollment, indicating possible delays in diagnosis and care, according to research results reported in the journal Blood Advances.
Adcetris, an Antibody-Drug Conjugate, Shows Promise As a Treatment for Pediatric Hodgkin Lymphoma
November 14, 2022
Positive results for Adcetris (brentuximab vedotin) were reported in The New England Journal of Medicine. Further research will include a look at the cost effectiveness of Adcetris.
Move Over, CAR-T. There’s Now a Bispecific Antibody Approved as a Late-Line Treatment for Multiple Myeloma.
October 26, 2022
The FDA approved Tecvayli (teclistamab) yesterday after approving two CAR-T therapies as late-line treatments for multiple myeloma earlier this year. Because it is ‘off the shelf,’ Tecvayli may have advantages over the CAR-T therapies, which are custom made for each patient and involve harvesting the patient's T cells.
CAR-T for Lymphoma Among the Topics at NCCN Meeting
October 25, 2022
Durability and toxicities such as cytokine release syndrome and immune effector-cell neurotoxicity syndrome are among the challenges.
How Poverty Affects Blood Cancer Patients
October 24, 2022
The study looked at cancer patients as a group, but senior author notes that ‘that treatments for blood cancers are very costly and many of them require treatment for long periods of time.’
Hodgkin Lymphoma Patients Have Higher Cardiovascular Mortality Risk Than Cancer
August 15, 2022
For almost all the patients with stage I or stage II disease, the cumulative incidence of CVD mortality exceeded that of classical Hodgkin lymphoma and other cancers, according to research results published in the journal Cancer.